Skip to content

Digital pathology and intraoperative imaging

Digital pathology and intraoperative imaging are specialist focus areas within Quint Healthcare. The work combines first-hand pathology and translational-research experience with product strategy, clinical evidence, European regulation and adoption in complex clinical workflows.

This is relevant to manufacturers, research organisations and investors working with microscopy, medical imaging, AI-enabled diagnostics, image-guided surgery, lasers, optical fibres and related software.

Why this matters now

Pathology and imaging sit at the intersection of three European transitions: health-workforce constraints, AI-enabled diagnostics and the gradual implementation of the European Health Data Space. The EHDS timetable anticipates cross-border exchange of medical images and laboratory results from 2031, while rules for secondary use of many health-data categories begin earlier.

The opportunity is considerable, but it does not remove the adoption problem. Technologies must fit specimen, imaging and reporting workflows, produce evidence that supports the intended claim and reduce or justify the work they introduce. This is precisely where clinical pathway expertise becomes commercially relevant.

Why clinical workflow matters

An imaging technology is not adopted because its image quality is impressive in isolation. It must fit a clinical pathway:

  • Which specimen, signal or image is acquired?
  • Who performs and interprets the examination?
  • When must the result be available?
  • How is the result documented and communicated?
  • Which existing step is replaced or changed?
  • Who remains accountable when software or a new modality contributes to the decision?
  • What evidence is needed for users, regulators and institutions to trust the result?

In pathology and intraoperative settings, these questions often cross departmental boundaries. A technically strong product can therefore fail to reach routine use because the workflow, ownership and evidence were treated as secondary matters.

Areas of expertise

Digital pathology

  • whole-slide imaging and viewing workflows;
  • image processing, alignment and analysis;
  • three-dimensional histology and research-to-clinical transition;
  • laboratory workflow and diagnostic-pathway assessment;
  • clinical requirements for pathology software and AI.

Intraoperative and confocal imaging

  • confocal microscopy for tissue assessment;
  • neurosurgical and neuropathological workflows;
  • intraoperative consultation and specimen pathways;
  • clinical-site strategy and user programmes;
  • evidence and adoption planning for novel modalities.

Image-guided surgery

  • real-time fluorescence and optical imaging;
  • differentiation of target and non-target tissue;
  • integration into surgical workflow;
  • clinical investigation and early-site strategy.

AI-enabled imaging and diagnostics

  • intended purpose and clinical claims;
  • clinical requirements and user needs;
  • evidence strategy and validation;
  • human oversight and workflow integration;
  • the interface between MDR or IVDR requirements and the EU AI Act.

The European Commission maintains current MDCG guidance on medical-device software, clinical evidence and the MDR/IVDR–AI Act interface.

Medical optics, lasers and fibres

  • clinical evaluation and post-market evidence;
  • medical and scientific application assessment;
  • product and indication strategy;
  • clinical-user and adoption work.

What Quint Healthcare contributes

Depending on the stage, work may include:

  • clinical need and pathway assessment;
  • intended-purpose and claim strategy;
  • clinician and user research;
  • product requirements and indication prioritisation;
  • clinical evidence and study strategy;
  • EU clinical evaluation and PMCF;
  • early-site and reference-site strategy;
  • clinical user groups and advisory boards;
  • medical due diligence and adoption-risk assessment.

Relevant experience

The foundation includes medical work in a university pathology institute, leadership of a translational research laboratory with digitised histology and tissue-analysis workflows, and academic research in oncology and pathology.

Industry and innovation work has included:

  • clinical and adoption work for intraoperative confocal imaging at the interface of neurosurgery and neuropathology;
  • digital-pathology market and product assessment;
  • support for microscopy companies moving towards clinical applications;
  • clinical evaluation and post-market work for medical lasers and optical fibres;
  • clinical needs work for AI-assisted radiology;
  • early clinical work in fluorescence-guided surgery;
  • investment assessment in digital pathology.

These experiences support a practical reading of the whole adoption path, from the clinical question to evidence, workflow and scale.

A practical starting point

Clinical pathway assessment

We map the technology against the diagnostic or surgical pathway it is intended to enter. The assessment identifies:

  • the relevant clinical decision and user;
  • the current workflow and bottleneck;
  • the proposed change in responsibility or timing;
  • the main evidence and regulatory questions;
  • the adoption risks that should be addressed before scaling.

Where appropriate, the work includes a small number of structured interviews with pathologists, surgeons, radiologists or laboratory stakeholders.

Boundaries and conflicts

Research performance does not by itself establish a clinical claim. If the technology is not ready for a clinical pathway, the assessment will state what is missing.

Because this is a specialised field, potential conflicts are reviewed before an engagement. Quint Healthcare does not work simultaneously on directly competing confidential strategies where the conflict cannot be managed.